National Institute of Mental Health Psychoactive Drug Screening Program

Therapeutic Approaches: Small Molecules, Peptides

Therapeutic Areas of Expertise: Cardiology, Metabolic Disorders, Neurological Disorders, Psychiatric Disorders, Pain, Autism-related disorders, imprinted disorders

Center/Program Highlights: The NIMH Psychoactive Drug Screening Program (NIMH-PDSP) provides a free screening service to qualified investigators. We provides screening of novel psychoactive compounds for pharmacological and functional activity at a large number cloned human or rodent CNS receptors, ion channels (including hERG), and transporters (including MDR-1). The NIMH PDSP will soon have the capacity to screen essentially all of the druggable non-olfactory GPCRs in the genome. Recent successes include: --The discovery that topoisomerase inhibitors unsilence a gene implicated in Angelman Syndrome (Huang et al, Nature 2012). --Crystal structure validation of kappa and ORL-1 opioid receptors (Wu et al, Nature 2012; Thompson et al, Nature 2012) --Discovery of b-arrestin biased dopamine D2 agonsts as potential novel therapeutics for schizophrenia-related disorders (Allen et al, PNAS 2011)

Sources of Funding: Federal/State, Philanthropy


Institutional Affiliation(s): Department of Pharmacology University of North Carolina Chapel Hill Medical School

4072 Genetic Medicine Building
Chapel Hill
North Carolina, 27705
United States

Center/Program Start Date: 1998

Number of Employees: 12